· Published by Health Canada · Official notice
This is duplicated text of a letter from Bristol-Myers Squibb Canada.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
12 May 2006
Subject: Updated safety information for TEQUIN* (gatifloxacin) and serious hypoglycemia and hyperglycemia
Dear Health Care Professional
Bristol-Myers Squibb (BMS) Canada, following discussions with Health Canada, would like to inform you of important updated safety information regarding the use of TEQUIN* (gatifloxacin).
In postmarketing experience worldwide, serious cases of both hypoglycemia and hyperglycemia have been reported in patients receiving TEQUIN. Although most of these cases were reversible, very rare events of dysglycemia were life-threatening, and a few resulted in fatal outcome. In light of these data Bristol-Myers Squibb Canada has revised the Product Monograph for TEQUIN as follows:
CONTRAINDICATIONS
The Product Monograph for TEQUIN has been revised to include a CONTRAINDICATION in diabetic patients due to serious reports of hypoglycemia and hyperglycemia (dysglycemia) in this population.
WARNINGS
A Serious Warning Box has been added to the WARNINGS section to identify other risk factors for dysglycemia (age ≥ 65 years, renal insufficiency, concomitant glucose altering medications) while taking TEQUIN, and to recommend close medical monitoring of patients with these risk factors. In addition, the box reminds physicians that patients with renal insufficiency require dose-adjustment.
Changes in Blood Glucose
DISTURBANCES OF BLOOD GLUCOSE, INCLUDING SYMPTOMATIC HYPOGLYCEMIA AND HYPERGLYCEMIA, HAVE BEEN REPORTED WITH TEQUIN, USUALLY IN DIABETIC PATIENTS. HOWEVER, HYPOGLYCEMIA AND PARTICULARLY HYPERGLYCEMIA HAVE OCCURRED IN PATIENTS WITHOUT A HISTORY OF DIABETES. IN ADDITION TO DIABETES, OTHER RISK FACTORS ASSOCIATED WITH DYSGLYCEMIA WHILE TAKING TEQUIN INCLUDE: OLDER AGE (≥ 65 YEARS OF AGE) , RENAL INSUFFICIENCY AND CONCOMITANT GLUCOSE-ALTERING MEDICATIONS (PARTICULARLY HYPOGLYCEMIC MEDICATIONS). FOR PATIENTS WITH RENAL INSUFFICIENCY DOSE ADJUSTMENT IS NECESSARY (SEE DOSAGE AND ADMINISTRATION - RENAL IMPAIRMENT TABLE 3). PATIENTS WITH THESE RISK FACTORS SHOULD BE CLOSELY MONITORED FOR GLUCOSE DISTURBANCES. IF SIGNS AND SYMPTOMS OF EITHER HYPOGLYCEMIA OR HYPERGLYCEMIA OCCUR IN ANY PATIENT BEING TREATED WITH TEQUIN, APPROPRIATE THERAPY MUST BE INITIATED IMMEDIATELY AND TEQUIN SHOULD BE DISCONTINUED.
Disturbances in glucose homeostasis, including an increase in serum insulin and decrease in serum glucose, sometimes associated with severe hypoglycemia and usually within 3 days of initiating therapy, have been reported in patients on TEQUIN. Hyperglycemia, in some cases severe, has also been observed, usually after the third day of TEQUIN administration.
During the postmarketing period, there have been very rare reports of serious disturbances of glucose homeostasis in patients treated with TEQUIN. These include: hyperosmolar non-ketotic hyperglycemic coma, diabetic ketoacidosis, hypoglycemic coma, convulsions and mental status changes (including loss of consciousness). Most of these events were reversible when appropriately managed, although a few resulted in fatal outcome (see CLINICAL PHARMACOLOGY and CONTRAINDICATIONS).
PRECAUTIONS
The PRECAUTIONS section has been updated to reflect the following
General
Geriatric Use
Drug- Drug Interactions
ADVERSE DRUG REACTIONS
The post-Marketing Adverse Event Reports section has been updated to include:
When prescribing or dispensing TEQUIN, we encourage you to discuss with your patients how they can detect changes in their blood glucose levels, and measures they should take if such changes occur.
Please refer to the Product Monograph for TEQUIN, including the Information for the Patient section, for a complete discussion of the Indications, Contraindications, Warnings, Precautions, Adverse Reactions and Dosage and Administration.
Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments.
The identification, characterization and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse reaction reporting programmes. Any occurrences of hypoglycemia or hyperglycemia or other serious or unexpected adverse reactions in patients receiving TEQUIN should be reported to Bristol-Myers Squibb or Health Canada at the following addresses:
Bristol-Myers Squibb Canada
2365 Côte-de-Liesse
Montréal, Québec
H4N 2M7
Tel : 866-463-6267
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
Email: MHPD_DPSC@hc-sc.gc.ca
Tel.: (613) 954-6522
Fax.: (613) 952-7738
Your professional commitment in this regard has an important role in protecting the well-being of your patients by contributing to early signal detection and informed use of drugs.
For a copy of the full Product Monograph on TEQUIN, please consult the Bristol Myers Squibb Canada website at www.bmscanada.ca.
If you require any further information on TEQUIN* (gatifloxacin) or for the full Product Monograph on TEQUIN*, please contact Bristol-Myers Squibb Canada Medical Information at 866-463-6267.
Sincerely,
original signed by
Dan Chiche, MD
Vice-President, Scientific Affairs
* TM of Bristol-Myers Squibb Company used under licence by Bristol-Myers Squibb Canada